Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchActive in the last 2 years

Bart Geboers

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8137-9299; OpenAlex author ID A5004755566. Sources: OpenAlex.

Their work

Papers
13 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
14
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: 4 papers · 2022: none · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper

Papers 13

  1. Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE t… Co-author DOI 10.1136/jitc-2024-010222↗
  2. MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE… First author DOI 10.1016/s2468-1253(24)00017-7↗
  3. Ablative treatments for locally advanced pancreatic cancer: the CROSSFIRE trial: Authors' reply. First author DOI 10.1016/s2468-1253(24)00162-6↗
  4. Tissue Resistance Decrease during Irreversible Electroporation of Pancreatic Cancer as a Biomarker for the Adaptive Immune Response and Survival. First author DOI 10.1016/j.jvir.2023.06.027↗
  5. Transcatheter CT arteriography-guided irreversible electroporation of locally advanced pancreatic adenocarcinoma: A pictorial essay. Co-author DOI 10.1111/1754-9485.13535↗
  6. Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. First author DOI 10.1007/s11912-021-01057-3↗
  7. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review. First author DOI 10.3390/cancers13071608↗
  8. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Meta… Co-author DOI 10.3390/cancers13153902↗
  9. Pancreatic Cancer and Immunotherapy: A Clinical Overview. First author DOI 10.3390/cancers13164138↗
  10. Irreversible Electroporation for Locally Advanced Pancreatic Cancer. First author DOI 10.1016/j.tvir.2020.100675↗
  11. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Stu… Co-author DOI 10.1148/radiol.2019191109↗
  12. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activati… Co-author DOI 10.1080/2162402x.2019.1652532↗
  13. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination? Co-author DOI 10.21037/cco.2019.10.05↗

Closest collaborators

The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hester J. Scheffer · 13 shared papers, 2019–2025 · strength 1.87
  2. Martijn Ruben Meijerink · 13 shared papers, 2019–2025 · strength 1.87
  3. Florentine E. F. Timmer · 10 shared papers, 2020–2025 · strength 1.57
  4. Tanja D. de Gruijl · 9 shared papers, 2019–2025 · strength 1.16
  5. Alette H. Ruarus · 8 shared papers, 2019–2025 · strength 1.03
  6. Anna M E Bruynzeel · 4 shared papers, 2021–2025 · strength 0.76
  7. Laurien G. P. H. Vroomen · 4 shared papers, 2019–2025 · strength 0.56
  8. Frank J. Lagerwaard · 2 shared papers, 2024–2025 · strength 0.37
  9. Johanna W. Wilmink · 2 shared papers, 2021 · strength 0.22
  10. Geert Kazemier M · 2 shared papers, 2019–2020 · strength 0.19
  11. Krijn P. van Lienden · 1 shared paper, 2020 · strength 0.10
  12. Eran van Veldhuisen · 1 shared paper, 2020 · strength 0.10
  13. Babs M. Zonderhuis · 1 shared paper, 2020 · strength 0.10
  14. Marc G. Besselink · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.